Physician profile
James J Lee
NPI 1457335564
$4,186.23
in general payments reported to CMS, 2019-2025
22 companies · $878 in 2025
The $878 reported for 2025 was more than what 79% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $129 · 2021: $297 · 2022: $394 · 2023: $720 · 2024: $1,336 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,093.42 | 2023-2025 | Inspire |
| Genzyme Corporation | $785.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $698.33 | 2019-2025 | Dupixent |
| Optinose US, INC. | $484.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $257.72 | 2021-2025 | Nucala |
| Stryker Corporation | $246.89 | 2019-2024 | Insignia |
| Acell, INC. | $125.00 | 2019 | |
| Aerin Medical INC. | $108.46 | 2022-2025 | |
| Royal Biologics, INC. | $103.87 | 2021 | |
| Alk-Abello, INC | $54.12 | 2019-2022 | |
| Davol INC. | $35.38 | 2019-2021 | |
| Cochlear Americas | $28.16 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Mallinckrodt Hospital Products INC. | $20.36 | 2025 | Acthar |
| Smith+Nephew, INC. | $18.66 | 2022 | |
| Janssen Biotech, INC. | $17.58 | 2025 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.37 | 2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $16.03 | 2025 | Tezspire |
| Axogen | $15.88 | 2019 | |
| Acclarent, INC | $15.80 | 2020 | |
| Ibsa Pharma INC. | $15.75 | 2024 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $15.03 | 2023 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.